Table 2

Association of increased ETAR expression with clinicopathological variables in primary breast cancer patients

Clinicopathological variablesETAR staining n positive/total (%)Pa
PT stage
 ≤pT253/120 (44.2)NSb; 0.642
 ≥pT321/39 (53.9)
Lymph node status
 Negative35/87 (40.2)NS; 0.137
 Positive36/69 (52.2)
Histologic grading
 I–II38/98 (38.8)0.009
 III36/60 (60.0)
ER status
 Positive52/96 (54.2)0.038
 Negative21/57 (36.8)
PR status
 Positive36/73 (49.3)NS; 0.760
 Negative37/79 (46.8)
Her-2/neu status
 Negative63/143 (44.0)0.003
 Positive10/11 (90.9)
MIB-1-labeling index
 ≤20%45/99 (45.5)NS; 0.590
 >20%27/54 (50.0)
Lymphovascular invasion
 No51/122 (41.8)0.030
 Yes23/37 (62.2)
Local recurrence
 No60/138 (43.5)0.047
 Yes14/21 (66.7)
Distant metastasis
 No46/114 (40.3)0.013
 Yes28/45 (62.2)
5-yr DFST
 Yes36/94 (38.3)0.030
 No24/41 (58.5)
  • a χ2 test.

  • b NS, not significant.